v3.26.3
Interim Condensed Consolidated Statements of Changes in Equity - Chemomab Therapeutics Ltd [Member] - USD ($)
$ in Thousands
Common Stock [Member]
Treasury Stock, Common [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Total [Member]
Balance at Dec. 31, 2022 $ (1,218) $ 101,260 $ (63,819) $ 36,223
Balance, shares at Dec. 31, 2022 [1] 232,636,700        
Treasury stock, common shares at Dec. 31, 2022   (11,640,460)      
Share-based compensation 1,491 1,491
Issuance of shares, net of issuance expenses 2,924 2,924
Issuance of shares, net of issuance expenses, shares [1] 51,458,000        
Sale of treasury shares at cost $ 1,218 (638) 580
Sale of treasury shares at cost, shares   11,640,460      
Net loss for the period (24,221) (24,221)
Balance at Dec. 31, 2023 105,675 (88,678) 16,997
Balance, shares at Dec. 31, 2023 [1] 284,094,700        
Treasury stock, common shares at Dec. 31, 2023        
Share-based compensation 617 617
Net loss for the period (13,945) (13,945)
Issuance of shares and pre-funded warrants, net of issuance costs 9,868 9,868
Issuance of shares and pre-funded warrants, net of issuance costs, shares [1] 93,037,520        
Balance at Dec. 31, 2024 [2],[3] 116,160 (102,623) 13,537
Balance, shares at Dec. 31, 2024 [1],[2],[3] 377,132,220        
Treasury stock, common shares at Dec. 31, 2024        
Share-based compensation [2],[3]   166 166
Issuance of shares, net of issuance expenses [2],[3]   13 13
Issuance of shares, net of issuance expenses, shares [2],[3] 124,240        
Net loss for the period [2],[3]   (3,323) (3,323)
Balance at Mar. 31, 2025 [2],[3]   116,339 (105,946) 10,393
Balance, shares at Mar. 31, 2025 [2],[3] 377,256,460        
Balance at Dec. 31, 2024 [2],[3] 116,160 (102,623) 13,537
Balance, shares at Dec. 31, 2024 [1],[2],[3] 377,132,220        
Treasury stock, common shares at Dec. 31, 2024        
Balance at Jun. 30, 2025 [2],[3]   117,702 (108,003) 9,699
Balance, shares at Jun. 30, 2025 [2],[3] 413,851,140        
Balance at Dec. 31, 2024 [2],[3] 116,160 (102,623) 13,537
Balance, shares at Dec. 31, 2024 [1],[2],[3] 377,132,220        
Treasury stock, common shares at Dec. 31, 2024        
Share-based compensation 623 623
Issuance of shares, net of issuance expenses 7,157 7,157
Issuance of shares, net of issuance expenses, shares [1] 180,171,640        
Net loss for the period (8,995) (8,995)
Exercise of Prefunded warrants   [4]
Exercise of Prefunded warrants, shares [1] 16,194,340        
Exercise of options 12 12
Exercise of options, shares [1] 1,883,120        
Balance at Dec. 31, 2025 [5],[6] 123,952 (111,618) 12,334
Balance, shares at Dec. 31, 2025 [1],[5],[6] 575,381,320        
Treasury stock, common shares at Dec. 31, 2025        
Balance at Mar. 31, 2025 [2],[3]   116,339 (105,946) 10,393
Balance, shares at Mar. 31, 2025 [2],[3] 377,256,460        
Share-based compensation [2],[3]   79 79
Issuance of shares, net of issuance expenses [2],[3]   1,282 1,282
Issuance of shares, net of issuance expenses, shares [2],[3] 20,337,840        
Net loss for the period [2],[3]   (2,057) (2,057)
Exercise of Prefunded warrants [2],[3]  
Exercise of Prefunded warrants, shares [2],[3] 16,194,340        
Exercise of options [2],[3]   2 2
Exercise of options, shares [2],[3] 62,500        
Balance at Jun. 30, 2025 [2],[3]   117,702 (108,003) 9,699
Balance, shares at Jun. 30, 2025 [2],[3] 413,851,140        
Balance at Dec. 31, 2025 [5],[6] 123,952 (111,618) 12,334
Balance, shares at Dec. 31, 2025 [1],[5],[6] 575,381,320        
Share-based compensation [5],[6]   134 134
Net loss for the period [5],[6]   (1,773) (1,773)
Exercise of RSA’s [5],[6]  
Exercise of RSA's, shares [5],[6] 648,880        
Balance at Mar. 31, 2026 [5],[6]   124,086 (113,391) 10,695
Balance, shares at Mar. 31, 2026 [5],[6] 576,030,200        
Balance at Dec. 31, 2025 [5],[6] 123,952 (111,618) 12,334
Balance, shares at Dec. 31, 2025 [1],[5],[6] 575,381,320        
Treasury stock, common shares at Dec. 31, 2025        
Balance at Jun. 30, 2026 [5],[6]   124,241 (115,556) 8,685
Balance, shares at Jun. 30, 2026 [5],[6] 579,648,600        
Balance at Mar. 31, 2026 [5],[6]   124,086 (113,391) 10,695
Balance, shares at Mar. 31, 2026 [5],[6] 576,030,200        
Share-based compensation [5],[6]   87 87
Issuance of shares, net of issuance expenses [5],[6]   68 68
Issuance of shares, net of issuance expenses, shares [5],[6] 2,780,800        
Net loss for the period [5],[6]   (2,165) (2,165)
Exercise of RSA’s [5],[6]  
Exercise of RSA's, shares [5],[6] 837,600        
Balance at Jun. 30, 2026 [5],[6]   $ 124,241 $ (115,556) $ 8,685
Balance, shares at Jun. 30, 2026 [5],[6] 579,648,600        
[1] 1 American Depositary Share (ADS) represents 80 Ordinary Shares.
[2] 1 American Depositary Share (ADS) represents 80 Ordinary Shares
[3] Ordinary shares no par value
[4] Less than 1 thousand
[5] 1 American Depositary Share (ADS) represents 80 Ordinary Shares
[6] Ordinary shares no par value